The foods were sent to one of Europe's top laboratories -
GeneScan in Germany - to look for GM maize which
cannot legally be sold in Europe. They analysed the foods
using Polymerase Chain Reaction (PCR) scanning firstly
for Monsanto's GM maize 'GA21' and then for other
unapproved varieties. They did this by looking for the
novel '35s/BAR' gene and when results for this gene were
positive, further PCR scanning was used to identify the
exact GM variety.
| Product | Purchase details | Monsanto GA21 |
| Asda own-brand | UK 12/10/00 | . |
| Safeway own- brand | UK 12/10/00 | . |
|
Phileas Fogg Authentic |
UK 17/10/00 | . |
According to the EU's Scientific Committee on Plants
(SCP), the novel protein has been tested on mice and the
whole grain has been used in a chicken feeding study.
Legal situation
Monsanto's GA21 maize is not approved in Europe.
Before GM crops can be sold in the EU they must obtain
both a marketing approval and a 'novel food' safety
approval. GA21 has neither.
Applications for EU marketing approval of this maize
were made by Monsanto in 1997 and 1998. In September
2000, the EU's Scientific Committee on Plants produced
an opinion on GA21, in which they stated that there is
no evidence to indicate that the placing on the market of
the modified maize (Zea mays) line GA21 with tolerance
to glyphosate herbicide is likely to cause any adverse
effects on human heath and the environment. However,
member states have yet to decide whether they agree with
this opinion, and approve GA21 for sale.
In 1998, Monsanto made an application for Novel Foods
safety approval (through the Netherlands). It is this which
determines whether a GM crop is considered safe for
consumption in Europe. When the UK's advisory
committee on GM foods (The Advisory Committee on
Novel Foods and Processes - ACNFP) looked at
Monsanto's application in March 2000, they concluded
that there was insufficient information on whether or not
the novel protein in GA21 could cause allergies.3 The
EU's top committee on GM foods, the Scientific
Committee on Foods (SCP) was asked to look at GA21 in
June 2000 but they have not yet produced an opinion.
According to a leaked report from Monsanto, seven
European countries have objected to the Novel Food
application for GA21 - Austria, Belgium, Denmark,
Greece, Ireland, Italy and Sweden.4
The GM maize resists insect pests by producing a novel
protein called CRY1Ac Delta-Endotoxin and production
of the novel PAT protein allows it to break down the
herbicide. These proteins are produced in the grains.
No application for food safety approval of DBT 418 has
been made in Europe. Dekalb did apply for permission to
market this maize in 1997. But when the UK's advisory
committee on GM foods (the ACNFP) considered the
application in 1998, they stated that they could not agree
to the marketing of it for animal feed. This is due to the
presence of four resistance genes for the antibiotic
ampicillin, and the fact that the genes contained structures
which could allow them to be used by bacteria in the
intestines of livestock unless they were completely broken
down by processing.5
At the end of 1998, the EU's scientific committee on
plants was asked to look at the safety of Dekalb's GM
maize, but in March 1999, before they had published an
opinion, Dekalb's application for marketing approval was
withdrawn.
FOE recommends that:
* food retailers remove all illegal foods from sale
* food manufacturers take immediate action to
ensure products are free of illegal GM
ingredients
* all shipments of maize, soya and oilseed rape
coming into Europe from countries known to
grow GM crops to be tested and fully-certified as
GM-free at port
* a full criminal investigation be carried out by the
appropriate authorities
* sufficient resources be given to the appropriate
enforcement authorities such as Trading
Standards
* a specific GM liability regime is introduced at an
EU level that channels liability to the biotech
companies.
Tel 0207 490 1555
Fax 0207 490 0881
E - mail: info@foe.co.uk
References